TRANSACTIONS WITH RELATED PERSONS
“The Board has adopted a written policy and procedures for approval of transactions between the Company and its directors, director nominees, executive officers, greater than 5% beneficial owners of Haemonetics common stock, and each of their respective immediate family members, where the amount involved in the transaction exceeds or is expected to exceed $120,000 in a single calendar year and the related person has or will have a direct or indirect material interest in the transaction (other than solely as a result of being a director or less than 10% beneficial owner of another entity). The policy, as amended from time to time, provides that the Audit Committee reviews transactions subject to the policy and determines (subject to Board ratification) whether or not to approve those transactions. In addition, in reviewing transactions subject to the policy, the Audit Committee considers, among other factors it deems appropriate:”
Read it in the proxyopen_in_new
TRANSACTIONS WITH RELATED PERSONS
“The material terms of the transaction, including whether the transaction with the related person is proposed to be entered into on terms no less favorable to Haemonetics than terms that could have been reached with an unrelated third-party;”
Read it in the proxyopen_in_new
TRANSACTIONS WITH RELATED PERSONS
“The approximate dollar value of the amount of the related person’s interest in the transaction without regard to the amount of any profit or loss;”
Read it in the proxyopen_in_new
TRANSACTIONS WITH RELATED PERSONS
“Whether the transaction is undertaken in the ordinary course of Haemonetics' business;”
Read it in the proxyopen_in_new
TRANSACTIONS WITH RELATED PERSONS
“The business purpose of, and the potential benefits to Haemonetics of, the transaction;”
Read it in the proxyopen_in_new
TRANSACTIONS WITH RELATED PERSONS
“Whether the transaction would impair the independence of a non-employee director;”
Read it in the proxyopen_in_new
TRANSACTIONS WITH RELATED PERSONS
“Required public disclosure, if any; and • Any other information regarding the transaction or the related person in the context of the proposed transaction that would be material to investors in light of the circumstances of the particular transaction.”
Read it in the proxyopen_in_new
TRANSACTIONS WITH RELATED PERSONS
“The Company is not aware of any transaction required to be reported under Item 404(a) of Regulation S-K promulgated by the SEC since the beginning of fiscal 2026, nor is the Company aware of any instances during the period in which the foregoing policies and procedures required review, approval or ratification of such transaction but for which such policies and procedures were not followed.”
Read it in the proxyopen_in_new